RxDoctor Payments Data

Kasra Sedarati, MD

Pulmonary Disease · Northridge, CANPI 1851634356

Payments from drug & device makers

$12,320in general payments, 2019–2025

Across 220 payments — averaging $56.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • Regeneron Healthcare Solutions, Inc.$922
  • Amgen$801
  • AstraZeneca$790
  • GSK$720
  • Boehringer Ingelheim$556
  • plus $2K from 16 others

What the payments were for

  • Speaking & faculty fees$1101%
  • Food & beverage$5,85848%
  • Education$6,35252%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,320 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$584,829
Medicare patients
601
Services billed
4,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate28$341,739
Tyvaso DpiTreprostinil13$304,535
TezspireTezepelumab-Ekko24$115,315
Trelegy ElliptaFluticasone/Umeclidin/Vilanter116$102,104
Breo ElliptaFluticasone/Vilanterol153$74,300
Dupixent PenDupilumab13$48,062
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$20,476
Pantoprazole Sodium30$12,953
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$10,514
EliquisApixaban33$9,810
Spiriva RespimatTiotropium Bromide14$9,681
Wixela InhubFluticasone Propion/Salmeterol38$7,219
Albuterol Sulfate HfaAlbuterol Sulfate155$6,566
BreynaBudesonide/Formoterol Fumarate18$4,467
Fluticasone-VilanterolFluticasone/Vilanterol13$4,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$556$351,42042 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$720$196,879298 claims
AstraZenecaTezspire, Breztri Aerosphere$790$125,82939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Northridge

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →